CytomX Q3 cash falls to $194.3M; revenue $16.9M; restructuring $7.1M; IND targets set for 2023

CytomX Therapeutics, Inc.

Cash and investments $194.3M as of Sep 30, 2022, down from $305.2M at Dec 31, 2021.
Revenue $16.9M for Q3 2022 vs $17.6M for Q3 2021, down ~4%.
R&D expense $30.4M, G&A $10.5M; restructuring charges $7.1M in Q3.
IND for CX-2051 and CX-801 expected H2 2023; CX-2029 sqNSCLC data update Q4 2022.
Company restructuring announced July 2022 to be completed by end of 2022; total ~$7.9M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CytomX Therapeutics, Inc. reported financial results for for the three months and nine months ended September 30, 2022.

Period: for the three months and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.